BioCentury | Feb 21, 2011
Company News

Oculus, Quinnova Pharmaceuticals Inc. sales and marketing update

Oculus granted Quinnova U.S. and Canadian rights to Epicyn Hydrogel for $500,000. The shelf-stable hypochlorous acid formulation that uses Oculus' Microcyn technology received FDA clearance earlier this month to manage burning, itching and pain associated...
BioCentury | Feb 14, 2011
Clinical News

Epicyn HydroGel regulatory update

FDA granted 510(k) clearance for Epicyn Hydrogel to manage burning, itching and pain associated with various types of dermatoses, including atopic and radiation dermatitis. Oculus hopes to partner the product and launch it this year....
Items per page:
1 - 2 of 2